8-K

Date: March 3, 2022

DBV TECHNOLOGIES S.A.

/s/ Sébastien Robitaille

Sébastien Robitaille

Chief Financial Officer

0001193125-22-064392.txt : 20220303 0001193125-22-064392.hdr.sgml : 20220303 20220303162914 ACCESSION NUMBER: 0001193125-22-064392 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20220303 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220303 DATE AS OF CHANGE: 20220303 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DBV Technologies S.A. CENTRAL INDEX KEY: 0001613780 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36697 FILM NUMBER: 22709342 BUSINESS ADDRESS: STREET 1: 177-181 AVENUE PIERRE BROSSOLETTE CITY: MONTROUGE STATE: I0 ZIP: 92120 BUSINESS PHONE: 33(0)155427878 MAIL ADDRESS: STREET 1: 177-181 AVENUE PIERRE BROSSOLETTE CITY: MONTROUGE STATE: I0 ZIP: 92120 8-K 1 d207740d8k.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

March 3, 2022

Date of Report (Date of earliest event reported)

DBV Technologies S.A.

(Exact name of registrant as specified in its charter)

France

001-36697

Not applicable

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)


177-181 avenue Pierre Brossolette
92120 Montrouge France		Not Applicable
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: +33 1 55 42 78 78

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Ordinary shares, nominal value €0.10 per share	n/a	The Nasdaq Stock Market LLC *
American Depositary Shares, each representing one- half of one ordinary share, nominal value €0.10 per share	DBVT	The Nasdaq Stock Market LLC

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.

Results of Operations and Financial Condition

On March 3, 2022, DBV Technologies S.A. (the “Company”) issued a press release announcing financial results and business highlights for the fiscal quarter and year ended December 31, 2021. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits


Exhibit No.		Description

99.1		Press Release issued March 3, 2022

104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EX-99.1 2 d207740dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

LOGO

DBV Technologies Reports Full Year 2021 Financial Results and Recent Business Updates

mVP Pivotal Protocol Complete and Ready for Submission to FDA

DBV Continues to Engage in Productive Exchanges with FDA

Cash Runway Extended into the First Quarter 2023

DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today reported financial results for the full year of 2021. The audit procedures have been substantially completed by the Company’s statutory auditors and financials were approved by the Board of Directors on March 3, 2022. The audit report will be issued by the Company’s auditors in March 2022.

DBV has extended its cash runway into the first quarter of 2023 as a result of continued financial diligence and cost containment measures. These targeted efforts adequately support the critical research and development work underway to advance the Viaskin platform. The protocol for the new Phase 3 pivotal study of the modified Viaskin Peanut (“mVP”) patch was completed at the end of February 2022 and has been prepared for FDA submission. The Company is currently engaged in fruitful discussions with FDA in preparation for protocol submission and review. DBV expects to complete protocol submission following further alignment with FDA.

“Initiating our new Phase 3 trial with the mVP is our top priority. We are pleased with our ongoing exchanges with FDA. In parallel to these discussions, DBV continues to maximize the efficiency of its spend. Based on our current assumptions, we have extended our cash runway into the first quarter of 2023,” said Daniel Tasse, Chief Executive Officer, DBV Technologies. “We expect that this cash position, combined with our continued discipline to reduce general and administrative expenses without sacrificing research and development, will give DBV sufficient time to gain alignment with FDA on the protocol for the mVP pivotal trial. DBV has been strategic in advancing its EPIT pipeline, and through these efforts, we aim to realize the full potential of the Viaskin technology for patients and families.

LOGO

Full-Year 2021 Financial Highlights ¹

Cash and Cash Equivalents

U.S. GAAP

IFRS

Year ended,

(in millions)

December 31,
2021

December 31,
2020 (*)

December 31,
2021

December 31,

2020 (*)

Net (decrease) / increase in cash and cash equivalents, of which

(119.1

)

3.1

(119.1

)

3.1

Net cash flow used in operating activities

(108.2

)

(165.6

)

(104.1

)

(160.9

)

Net cash flow provided by / (used in) investing activities

(0.4

)

(2.9

)

(0.4

)

(2.9

)

Net cash flow provided by / (used in) financial activities

0.3

149.5

(3.9

)

144.8

Effect of exchange rate changes on cash and cash equivalents

(10.7

)

22.0

(10.7

)

22.0

Net cash and cash equivalents at the end of the period

77.3

196.4

77.3

196.4

(*)	including $150.0 million cash flows provided by 1Q20 capital increase

As of December 31, 2021, cash and cash equivalents were $77.3 million, compared to $196.4 million as of December 31, 2020. In 2021, cash used in operating activities was $(108.2) million under U.S. GAAP and $(104.1) million under IFRS compared to $(165.6) million under U.S. GAAP and $(160.9) million under IFRS in 2020.

The 35% decrease in net cash used in operating activities between the years ended December 31, 2021 and 2020 reflects the Company’s continued implementation of budget discipline measures.

Over the past 2 years, DBV reduced its net cash used in operating activities by 54%.

Net cash used in operating activities, including restructuring amounts paid as part of the global restructuring plan launched in June 2020 (in millions of $)


				% Change vs						% Change vs
	FY21			FY20			2H21			1H21			2H20			1H20

Net cash flow used in operating activities - U.S.GAAP		(108.2	)		(34.7	)%		(41.7	)		(37.3	)%		(45.0	)%		(53.6	)%
Net cash flow used in operating activities - IFRS		(104.1	)		(35.3	)%		(40.0	)		(37.6	)%		(45.4	)%		(54.3	)%

The Company’s annual consolidated financial statements are prepared in accordance with both generally accepted accounting principles in the U.S. (“U.S. GAAP”) and International Financial Reporting Standards (“IFRS”) as adopted by the European Union. Unless otherwise indicated, the financial figures presented in the Full Year 2021 Financial Highlights comply with both U.S GAAP and IFRS financial statements. Differences between U.S. GAAP and IFRS consolidated financial statements are mainly due to discrepancies arising from the application of lease accounting standards.

LOGO

Cash flows used in investment activities were $(0.4) million in 2021, compared to $(2.9) million in 2020.

Cash from financing activities were $0.3 million under U.S. GAAP and $(3.9) million under IFRS compared to net cash flows provided by financing activities of $149.5 million under U.S. GAAP and $144.8 million under IFRS in 2020, including $150.0 million received in connection with DBV’s follow-on public offering of its securities in the first quarter of 2020.

DBV has continued to practice financial diligence and implemented further cost containment strategies. Based on its current operations, as well as its plans and assumptions as revised pursuant to its change of strategy announced in December 2021, DBV expects that its current cash and cash equivalents will support its operations into the first quarter of 2023.

Operating Income is primarily generated from DBV’s Research Tax Credit (French Crédit Impôt Recherche, or CIR) and from revenue recognized by DBV under its collaboration agreement with Nestlé Health Science. Operating income was $5.7 million, for the year ended December 31, 2021, compared to $11.3 million the year ended December 31, 2020. The decrease in operating income is primarily attributable to the revision of the revenue recognized under Nestlé’s collaboration agreement, as the Company updated its measurement of progress of its Phase II clinical study conducted as part of the contract due to recruitments’ delays.

Operating Expenses


	U.S. GAAP				IFRS
(in thousands of $)	December 31,				December 31,
	2021		2020		2021		2020
Operating expenses :
Research and development expenses		(70,336)		(101,607)		(70,104)		(101,346)
Sales and marketing expenses		(4,387)		(9,879)		(4,403)		(9,747)
General and administrative expenses		(30,520)		(35,081)		(30,385)		(35,137)
Restructuring income (expenses)		920		(23,552)		920		(22,994)

Total Operating expenses		(104,323)		(170,118)		(103,972)		(169,224)

Operating Expenses for the year ended December 31, 2021, were $104.3 million under U.S. GAAP and $104.0 million under IFRS, compared to $170.1 million under U.S. GAAP and $169.2 million under IFRS for the year ended December 31, 2020. The decrease in operating expenses for both periods is mainly attributable to the decrease in external clinical-related expenses and professional fees due to the budget discipline measures taken by DBV, as well as the decrease in employee-related costs, which is directly related to the workforce reduction DBV implemented as part of its 2020 global restructuring plan.

LOGO

Excluding restructuring and share-based payments expenses, employee-related costs decreased by $19.2 million, from $42.0 million for the year ended December 31, 2020 to $22.7 million for the year ended December 31, 2021, under U.S. GAAP. Under IFRS, excluding share-based payments expenses, employee-related costs decreased by $19.5 million, from $42.3 million for the year ended December 31, 2020 to $22.8 million for the year ended December 31, 2021.

The average headcount decreased by 63% between the two periods, from 270 full-time equivalent employees for the year ended December 31, 2020 to 101 for the year ended December 31, 2021. As of December 31, 2021, DBV had 92 employees.

Net Loss and Net Loss Per Share


	U.S. GAAP						IFRS
($ in thousands)	December 31,						December 31,
	2021			2020			2021			2020

Net (loss)	$	(97,809	)	$	(159,555	)	$	(98,052	)	$	(159,665	)
Basic / diluted net loss per share ($/share)	$	(1.78	)	$	(2.95	)	$	(1.79	)	$	(2.95	)

For the year ended December 31, 2021, net loss was $(97.8) million under U.S. GAAP and $(98.1) million under IFRS, compared to a net loss of $(159.6) million and $(159.7) million, respectively, for the year ended December 31, 2020.

On a per share basis, net loss (based on the weighted average number of shares outstanding over the period) was $(1.78) under U.S. GAAP and $(1.79) under IFRS for the year ended December 31, 2021.

Conference Call Information:

DBV will host a conference call and live audio webcast on Thursday, March 3, 2022, at 5:00 p.m. ET to report fourth quarter and full year 2021 financial results and review recent business updates.

This call is accessible via the below teleconferencing numbers, followed by the reference ID: 50283860

●

United States: 1 (866) 939-3921

●

Canada: 1 (866) 215-5508

●

United Kingdom: 0808 238 9578

●

France: 0805 102 604

A live webcast of the call will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV’s website after the event.

LOGO

CONDENSED STATEMENT OF CONSOLIDATED FINANCIAL POSITION (unaudited)

($ in thousands)


	U.S. GAAP²						IFRS³
	December 31,						December 31,
	2021			2020			2021			2020
Assets	$	146,723		$	272,246		$	146,323		$	272,019
of which cash and cash equivalents		77,301			196,352			77,301			196,352
Liabilities		47,449			66,754			47,294			66,631
Shareholders’ equity	$	99,274		$	205,491		$	99,030		$	205,388
of which net result		(97,809	)		(159,555	)		(98,052	)		(159,665	)

CONDENSED STATEMENT OF CONSOLIDATED OPERATIONS AND COMPREHENSIVE LOSS (unaudited)

($ in thousands, except per share data)


	U.S. GAAP²						IFRS³
	December 31,						December 31,
	2021			2020			2021			2020
Revenue	$	5,708		$	11,276		$	5,708		$	11,276
Operating expenses :
Research and development expenses		(70,336	)		(101,607	)		(70,104	)		(101,346	)
Sales and marketing expenses		(4,387	)		(9,879	)		(4,403	)		(9,747	)
General and administrative expenses		(30,520	)		(35,081	)		(30,385	)		(35,137	)
Restructuring income (expenses)		920			(23,552	)		920			(22,994	)

Total Operating expenses		(104,323	)		(170,118	)		(103,972	)		(169,225	)

Financial income (expenses)		425			(724	)		(169	)		(1,727	)
Income tax		381			10			381			10

Net (loss)	$	(97,809	)	$	(159,555	)	$	(98,052	)	$	(159,665	)


Basic/diluted Net loss per share attributable to shareholders	$	(1.78	)	$	(2.95	)	$	(1.79	)	$	(2.95	)

²	Unaudited financial statements prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”).

³	Unaudited financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”) as adopted by the European Union.

LOGO

CONDENSED STATEMENT OF CONSOLIDATED CASH FLOW (unaudited)

($ in thousands)


	U.S. GAAP⁴						IFRS⁵
	December 31,						December 31,
	2021			2020			2021			2020

Net cash flow used in operating activities	$	(108,242	)	$	(165,607	)	$	(104,058	)	$	(160,891	)
Net cash flows used in investing activities		(433	)		(2,865	)		(433	)		(2,865	)
Net cash flows provided by financing activities		274			149,548			(3,909	)		144,837

Effect of exchange rate changes on cash and cash equivalents		(10,651	)		22,022			(10,650	)		22,017

Net (decrease) / increase in cash and cash equivalents		(119,051	)		3,097			(119,051	)		3,097

Net cash and cash equivalents at the beginning of the period		196,352			193,255			196,352			193,255

Net cash and cash equivalents at the end of the period	$	77,301		$	196,352		$	77,301		$	196,352

About DBV Technologies

DBV Technologies is developing Viaskin^™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT^™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Summit, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

⁴	Unaudited financial statements prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”).

⁵	Unaudited financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”) as adopted by the European Union.

LOGO

Forward Looking Statements

This press release may contain forward-looking statements and estimates, including statements regarding DBV’s forecast of its cash runway, designs of DBV’s anticipated clinical trials, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, and the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, including the impact of the COVID-19 pandemic, and DBV’s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the French Autorité des Marchés Financiers (“AMF”), DBV’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 17, 2021, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

Investor Contact

Anne Pollak

DBV Technologies

+1 857-529-2363

anne.pollak@dbv-technologies.com

Media Contact

Angela Marcucci

DBV Technologies

+1 646-842-2393

angela.marcucci@dbv-technologies.com

EX-101.SCH 3 dbvt-20220303.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 dbvt-20220303_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 dbvt-20220303_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Entity Address, Country Entity Address, Country Entity Tax Identification Number Entity Tax Identification Number Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Address, City or Town Entity Address, City or Town City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Fair Value Measured at Net Asset Value Per Share [Member] Fair Value Measured at Net Asset Value Per Share [Member] Adr [Member] Adr [Member] EX-101.PRE 6 dbvt-20220303_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g207740page08.jpg GRAPHIC begin 644 g207740page08.jpg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g207740page4.jpg GRAPHIC begin 644 g207740page4.jpg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end GRAPHIC 9 g207740page4a.jpg GRAPHIC begin 644 g207740page4a.jpg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htm IDEA: XBRL DOCUMENT

Document and Entity Information	Mar. 03, 2022
Document And Entity Information [Line Items]
Security Exchange Name	NASDAQ
Entity Address, Country	FR
Entity Tax Identification Number	00-0000000
Amendment Flag	false
Entity Central Index Key	0001613780
Document Type	8-K
Document Period End Date	Mar. 03, 2022
Entity Registrant Name	DBV Technologies S.A.
Entity Incorporation State Country Code	I0
Entity File Number	001-36697
Entity Address, Address Line One	177-181 avenue Pierre Brossolette
Entity Address, Postal Zip Code	92120
Entity Address, City or Town	Montrouge
City Area Code	33
Local Phone Number	1 55 42 78 78
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Fair Value Measured at Net Asset Value Per Share [Member]
Document And Entity Information [Line Items]
Security Exchange Name	NASDAQ
Security 12b Title	Ordinary shares, nominal value €0.10 per share
Adr [Member]
Document And Entity Information [Line Items]
Security Exchange Name	NASDAQ
Security 12b Title	American Depositary Shares, each representing one- half of one ordinary share, nominal value €0.10 per share
Trading Symbol	DBVT

XML 11 d207740d8k_htm.xml IDEA: XBRL DOCUMENT 0001613780 2022-03-03 2022-03-03 0001613780 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2022-03-03 2022-03-03 0001613780 dei:AdrMember 2022-03-03 2022-03-03 NASDAQ NASDAQ FR 00-0000000 false 0001613780 8-K 2022-03-03 DBV Technologies S.A. I0 001-36697 177-181 avenue Pierre Brossolette 92120 Montrouge 33 1 55 42 78 78 false false false false Ordinary shares, nominal value €0.10 per share NASDAQ American Depositary Shares, each representing one- half of one ordinary share, nominal value €0.10 per share DBVT false EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 3 118 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d207740d8k.htm d207740dex991.htm dbvt-20220303.xsd dbvt-20220303_def.xml dbvt-20220303_lab.xml dbvt-20220303_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d207740d8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "dbvt-20220303_def.xml" ] }, "inline": { "local": [ "d207740d8k.htm" ] }, "labelLink": { "local": [ "dbvt-20220303_lab.xml" ] }, "presentationLink": { "local": [ "dbvt-20220303_pre.xml" ] }, "schema": { "local": [ "dbvt-20220303.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 6, "total": 6 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 2, "nsprefix": "dbvt", "nsuri": "http://www.dbv-technologies.com/20220303", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d207740d8k.htm", "contextRef": "duration_2022-03-03_to_2022-03-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:SecurityExchangeName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d207740d8k.htm", "contextRef": "duration_2022-03-03_to_2022-03-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:SecurityExchangeName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dbvt_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://www.dbv-technologies.com/20220303", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dbvt_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://www.dbv-technologies.com/20220303", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AdrMember": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "American Depositary Receipt (or American Depositary Share, ADS).", "label": "Adr [Member]", "terseLabel": "Adr [Member]" } } }, "localname": "AdrMember", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measured at Net Asset Value Per Share [Member]", "terseLabel": "Fair Value Measured at Net Asset Value Per Share [Member]" } } }, "localname": "FairValueMeasuredAtNetAssetValuePerShareMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.dbv-technologies.com//20220303/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-3" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r7": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 19 0001193125-22-064392-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-064392-xbrl.zip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end